奥扎格雷联合低分子肝素钙治疗脑血栓的疗效及临床价值

Efficacy and Clinical Value of Ozagrel Combined with Low Molecular Heparin Calcium in the Treatment of Cerebral Thrombosis

目的 探究脑血栓患者采用奥扎格雷与低分子肝素钙联合治疗方案的疗效。方法 随机选取2018年12月—2019年12月聊城市退役军人医院收治的脑血栓患者200例作为研究对象,采取随机数表法分为两组,100例接受低分子肝素钙治疗为对照组,100例接受低分子肝素钙治疗基础上联合使用奥扎格雷为治疗组。比较两组临床疗效、血液流变学、血栓形成相关血液因子、神经功能及生活质量、不良反应。结果 治疗组有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组vWF与GMP140水平均比治疗前明显降低,且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组神经功能NIHSS量表与生活质量SF-36量表评分比较,差异无统计学意义(P>0.05);治疗后两组NIHSS量表评分减少,SF-36量表评分增加,且治疗组NIHSS量表评分(8.34±1.02)分低于对照组(10.45±1.25)分,SF-36量表评分(86.36±5.34)分高于对照组(80.36±4.67)分,差异有统计学意义(t=13.078、8.458,P<0.001)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 联合奥扎格雷与低分子肝素钙对脑血栓患者进行治疗,临床疗效好,具有很高的临床价值。

Objective To investigate the efficacy of combined treatment regimen of Ozagrel and Low Molecular Heparin Calcium in patients with cerebral thrombosis.Methods 200 patients with cerebral thrombosis admitted to Liaocheng Veterans Hospital from December 2018 to December 2019 were randomly selected as the research subjects,and were randomly divided into two groups using a random number table method.100 cases received Low Molecular Heparin Calcium treatment as the control group,and 100 cases received Low Molecular Heparin Calcium treatment based on the combined use of Ozagrel as the treatment group.The clinical efficacy,blood rheology,thrombosis-related blood factors,neurological function and quality of life,and adverse effects of two groups were compared.Results The effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of vWF and GMP140 in both groups were significantly lower than before treatment,and the treatment group was lower than the control group,the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups in terms of neurological function NIHSS scale and quality of life SF-36 scale(P>0.05);after treatment,the NIHSS scale scores of the two groups decreased,while the SF-36 scale scores increased.The NIHSS scale scores of the treatment group(8.34±1.02)points were lower than those of the control group(10.45±1.25)points,while the SF-36 scale scores(86.36±5.34)points were higher than those of the control group(80.36±4.67)points,the difference was statistically significant(t=13.078,8.458,P<0.001).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Combining Ozagrel with Low Molecular Heparin Calcium for the treatment of patients with cerebral thrombosis is clinically effective and has high clinical value.